Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

• Status: Active, not recruiting
• Trial end date: 2022-08-01

Summary

This study adds irinotecan, temozolomide and bevacizumab to the chemotherapy regimen currently used to treat Desmoplastic small round cell tumor (DSRCT). The investigators are doing this study to find out what effects, good and/or bad, the combination of irinotecan, temozolomide and bevacizumab has on the patient and the DSRCT cancer.

• Phase: Early Phase 1

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: Genentech, Inc.
• Treatments: Alkylating Agents; Bevacizumab; Camptothecin; Dacarbazine; Irinotecan; Temozolomide